Tag: disability

Most Home Health Aides Need to Work, Even When Lacking PPE

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Sue Williams-Ward — pictured with her granddaughter Tamarya Burnett — was...

COVID-19 Risks No Higher in Patients With Multiple Sclerosis

The risk of severe outcomes from COVID-19 infection in patients with multiple sclerosis seems to align with that seen in the general population, new US...

COVID-19 Vaccine Should Go to HCWs First, NAS Panel Says

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Anticipating an initial short supply of COVID-19 vaccines, a prominent scientific...

Intensive Blood Pressure Lowering Potentially Harmful in ICH

Intensive lowering of systolic blood pressure (SBP) for patients with intracerebral hemorrhage (ICH) whose initial SBP is excessively high does not improve outcomes and is...

Masitinib Impresses in ‘Nonactive’ Progressive MS

The investigational drug, masitinib (AB Science), which has a completely new mechanism of action for multiple sclerosis (MS), has shown a positive result in slowing...

Smoking Increases Risk of High Plasma NfL Levels in MS

A new study has found that patients with multiple sclerosis (MS) who smoke cigarettes regularly have an increased risk of higher plasma neurofilament light levels...

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Measuring serum levels of neurofilament light chain (NfL) is an effective way of detecting disease activity and the need to optimize treatment in patients with...

App for MS Aims to Capture Elusive Signals of Progression

Investigators in Switzerland are testing an application for smartphones that they hope will elucidate subtle signs of disease progression in multiple sclerosis (MS)—beyond what standard...

Ofatumumab Phase 3 Multiple Sclerosis Trials Published

Two phase 3 clinical trials showing impressive results with the new subcutaneously-delivered, B-cell depleting multiple sclerosis anti-CD20 mononclonal antibody ofatumumab (Arzerra) have now been published...

CHMP Backs Bupivacaine/Meloxicam (Zynrelef) for Postop Pain

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the fixed-dose combination of bupivacaine and...

AAP Releases New Policy on Barrier Protection for Teens

For adolescent patients, routinely take a sexual history, discuss the use of barrier methods, and perform relevant examinations, screenings, and vaccinations, according to a new...

MS Disability, Not Drug Therapy, Tied to Worse COVID-19 Outcomes

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. In patients with MS, disability, age, and obesity were the main...

Ofatumumab Shows High Elimination of Disease Activity in MS

With ofatumumab (Arzerra, Novartis), a fully human anti-CD20 monoclonal antibody, there is a greater likelihood of there being no evidence of disease activity (NEDA-3) for...

Initial High-Efficacy MS Therapy Tied to Less Disability Later

Starting treatment for relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with lower long-term disability compared with a step-wise increase to reach more...

Five-Year Siponimod Data Support Early MS Treatment

Among patients with secondary progressive multiple sclerosis (MS) who received siponimod or placebo during a double-blind trial and entered an open-label extension, those who received...